Modality
mRNA
MOA
PLK4i
Target
IL-17A
Pathway
Incretin
CholangiocarcinomaPancreatic CaFL
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Sep 2029
Phase 2Current
NCT03696668
2,464 pts·Pancreatic Ca
2019-10→2029-09·Not yet recruiting
2,464 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-073.4y awayPh2 Data· Pancreatic Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2029-09-07 · 3.4y away
Pancreatic Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03696668 | Phase 2 | Pancreatic Ca | Not yet recr... | 2464 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| CSL-8235 | CSL Limited | Phase 1/2 | IL-17A |